Claravis Capsule, Liquid Filled
FDA Label NDC 0555-1054

43 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Claravis (NDC 0555-1054). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: embryo-fetal toxicity - contraindicated in pregnancy, 1 indications and usage, 2.1 evaluations prior to prescribing and use of claravis, 2.2 recommended dosage, 2.3 recommended duration of use, 3 dosage forms and strengths, 4 contraindications, 5.1 embryo-fetal toxicity, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.